TLDR:
- Attovia Therapeutics closed a $105 million Series B financing round, bringing their total capital raised to $165 million.
- The funding will be used to advance lead programs, expand the pipeline, and develop the ATTOBODY platform.
Attovia Therapeutics recently closed an oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives, with participation from several new investors. The total capital raised by the company since its launch in June 2023 now stands at $165 million. The funds will be utilized to advance the Company’s lead programs, ATTO-1310 and ATTO-002, expand the immunology and inflammation pipeline, and further develop the ATTOBODY platform.
The Company’s lead programs, ATTO-1310 and ATTO-002, represent potential best-in-class therapeutics for immune-mediated diseases. ATTO-1310 is currently in IND enabling studies and is expected to enter the clinic by the end of 2024, while ATTO-002 is set to progress to IND in 2025. Attovia is also working on discovery stage programs to expand the ATTOBODY platform footprint to novel, difficult-to-drug targets.
Colin Walsh, Managing Director at Goldman Sachs Alternatives, has been appointed to Attovia’s Board of Directors. Walsh expressed confidence in Attovia’s position as a leader in developing biologics for patients with immune-mediated diseases and lauded the company’s impressive pipeline built using the ATTOBODY platform. The Company aims to advance its programs and pipeline further with the support of a strong group of investors.
